ABSTRACT
PURPOSE: Breast cancer is the most commonly occurring cancer among women worldwide, and therefore, improved approaches for its early detection are urgently needed. As microRNAs (miRNAs) are increasingly recognized as critical regulators in tumorigenesis and possess excellent stability in plasma, this study focused on using miRNAs to develop a method for identifying noninvasive biomarkers. METHODS: To discover critical candidates, differential expression analysis was performed on tissue-originated miRNA profiles of 409 early breast cancer patients and 87 healthy controls from The Cancer Genome Atlas database. We selected candidates from the differentially expressed miRNAs and then evaluated every possible molecular signature formed by the candidates. The best signature was validated in independent serum samples from 113 early breast cancer patients and 47 healthy controls using reverse transcription quantitative real-time polymerase chain reaction. RESULTS: The miRNA candidates in our method were revealed to be associated with breast cancer according to previous studies and showed potential as useful biomarkers. When validated in independent serum samples, the area under curve of the final miRNA signature (miR-21-3p, miR-21-5p, and miR-99a-5p) was 0.895. Diagnostic sensitivity and specificity were 97.9% and 73.5%, respectively. CONCLUSION: The present study established a novel and effective method to identify biomarkers for early breast cancer. And the method, is also suitable for other cancer types. Furthermore, a combination of three miRNAs was identified as a prospective biomarker for breast cancer early detection.
Subject(s)
Female , Humans , Area Under Curve , Biomarkers , Biomarkers, Tumor , Breast Neoplasms , Breast , Carcinogenesis , Data Mining , Early Detection of Cancer , Genome , Methods , MicroRNAs , Plasma , Prospective Studies , Real-Time Polymerase Chain Reaction , Reverse Transcription , Sensitivity and SpecificityABSTRACT
Patient,competition and change are characteristics of the modern hospital manage environment,clinical laboratory management must be more scientific and more religious.This article lists the main items of clinical laboratory management using ISO15189,and raised some idea on clinical laboratory management using ISO15189 and points out the difficulties of popularization using ISO15189 in clinical laboratory management.
ABSTRACT
Objective To certify the linear range of WBC measured by CD3700.Methods Use the white stratum of blood after centrifugation.Then,the high value specimens were diluted with saline to get a series of samples with different concentrations.Every specimen was measured twice in order to keep the sequence of specimens randomly.The perform outlier test,polynomial regression analysis,and the random error estimation were carried out.Results There was no outlier in the results.It was demonstrated by polynomial regression to be linear from(0～219)?109 L-1.The random error was within the allowable limit of 1/4CLIA'88(3.75%).Conclusion The linear range of WBC measured by CD3700 is just like that of the manufacturer claims.
ABSTRACT
<p><b>OBJECTIVE</b>To evaluate the risk of nasopharyngeal carcinoma (NPC) through EB virus antibody profile by enzyme linked immunosorbent assay (ELISA).</p><p><b>METHODS</b>EBNA 1/IgA, EBNA 1/IgG and zta/IgG by ELISA and VCA/IgA by immmunoenzymatic method were detected in 121 NPC patients and 332 healthy subjects (HS) in the Pearl river estuary.</p><p><b>RESULTS</b>The sensitivity rates were 85%, 83% and 79% for EBNA 1/IgA, EBNA 1/IgG and zta/IgG, all three of which if combined was the highest 92%. The specificity rates were 86%, 86% and 80% for EBNA 1/IgA, EBNA 1/IgG and zta/IgG, all three of which if combined was also the highest 93%. According to the level of odds ratio, nasopharyngeal carcinoma risk could be divided into 3 groups: low, moderate and high-risk groups. 93% of HS had low risk of NPC with the odds ratio 0.0 to 0.3. 0.4% of HS had high risk of NPC with the odds ratio of 137.9%.</p><p><b>CONCLUSION</b>ELISA is more objective than the traditional immunoenzymatic method in the detection and diagnosis of NPC. The combination of EBNA 1/IgA, EBNA 1/IgG and zta/IgG is able to evaluate the risk of NPC.</p>